Magic mushroom compound meets therapy in new depression trial
NCT ID NCT07281352
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining psilocybin (the active ingredient in magic mushrooms) with cognitive behavioral therapy can help people with major depression. Fifty adults aged 21-60 with current depression will receive two doses of psilocybin and either 12 sessions of CBT or 6 sessions of supportive therapy. The goal is to see if this approach is feasible, acceptable, and potentially helpful for easing depressive symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- psilocybin
- What this could lead to
- If it works, this could point toward a new treatment option for depression that combines therapy with a psychedelic drug.
- What could go wrong
- This is an early-phase trial with only 50 participants, so results may not apply to everyone. Psilocybin can cause intense psychological effects and is not yet proven effective for depression.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DIORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UCLA Semel Institute
RECRUITINGLos Angeles, California, 90095, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.